Atrial fibrillation (AF) is the most common arrhythmia in the general population and it is associated with increased mortality and morbidity. In order to restore sinus rhythm, AF cardioversion (CV) can be performed after an adequate anticoagulation (OAC) period, with the aim of reducing thromboembolic risk related to the procedure. Safety and effectiveness of non-vitamin K antagonist (NOACs) in the setting of AF cardioversion has been evaluated in post hoc analysis of the large trials on NOACs and in specifically designed studies. Data available from the literature is missing specific considerations on AF patients on low dose NOACs scheduled for elective AF cardioversion.
The aim of our study is to evaluate the prevalence of left atrial abnormalities such as left atrial/left atrial appendage thrombi or spontaneous dense echo contrast in AF patients undergoing a transesophageal echocardiography before CV.


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account